Caribou Biosciences Files 8-K on Operations and Finances

TL;DR

CRBU filed an 8-K on 7/16 detailing operations, financials, and exit costs.

AI Summary

On July 16, 2024, Caribou Biosciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers costs associated with exit or disposal activities and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Berkeley, California.

Why It Matters

This 8-K filing provides crucial updates on Caribou Biosciences' financial health and operational activities, which can influence investor decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, not indicating immediate significant risk.

Key Players & Entities

• Caribou Biosciences, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Berkeley, California (location) — Principal Executive Offices
• July 16, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global
• $311.8 million — e Company expects to report that it had $311.8 million in cash, cash equivalents, and marketab
• $0.5 million — y estimates it will incur approximately $0.5 million to $1.0 million in costs, consisting pr
• $1.0 million — ill incur approximately $0.5 million to $1.0 million in costs, consisting primarily of cash

Filing Documents

• crbu-20240716.htm (8-K) — 31KB
• 0001619856-24-000054.txt ( ) — 161KB
• crbu-20240716.xsd (EX-101.SCH) — 2KB
• crbu-20240716_lab.xml (EX-101.LAB) — 23KB
• crbu-20240716_pre.xml (EX-101.PRE) — 13KB
• crbu-20240716_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On July 16, 2024, Caribou Biosciences, Inc. (the "Company" or "Caribou") reported in Item 2.05 below that, on a preliminary unaudited basis, the Company expects to report that it had $311.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This estimate of cash, cash equivalents, and marketable securities is its preliminary estimate based on currently available information and does not present all necessary information for an understanding of the Company's financial condition as of June 30, 2024 or its results of operations for the three and six months ended June 30, 2024. As the Company completes its quarter-end financial close process and finalizes its financial statements for the three and six months ended June 30, 2024, the Company may be required to make significant adjustments in a number of areas that may result in the estimate provided herein being different than the final reported cash, cash equivalents, and marketable securities as of June 30, 2024.

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On July 16, 2024, the Company discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions, or approximately 12%. The Company is undertaking this reduction to extend its cash runway and focus resources on its allogeneic CAR-T cell therapy platform and on rapidly advancing four oncology and autoimmune disease clinical programs through multiple milestones expected in 2024 and 2025. The Company expects to substantially complete the reduction by the end of the third quarter of 2024. The workforce reduction, together with other cost containment measures, is expected to extend the Company's cash runway by at least six months into the second half of 2026. On a preliminary unaudited basis, Caribou expects to report that it had $311.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024. In connection with the workforce reduction, the Company currently estimates it will incur approximately $0.5 million to $1.0 million in costs, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, which the Company expects to recognize in the third quarter of 2024. The estimates of costs and expenses that the Company expects to incur in connection with the CAR-NK platform discontinuation and workforce reduction are subject to a number of assumptions, and actual results may differ materially. The Company may also incur costs not currently contemplated due to events that may occur as a result of, or that are associated with, this decision.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, the Company's estimated cash, cash equivalents, and marketable securities position as of June 30, 2024; the Company's expected cash runway anticipated costs associated with the workforce reduction, including specific categories of costs and future cash expenditures and the timing of when the reduction is expected to be completed and the anticipated costs recognized and the Company's position, plans, strategies, and timelines for the continued and future clinical development of its CAR-T cell therapies. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of the Company's research and development programs, preclinical studies, and clinical trials; and the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of the Company's product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available and is fully evaluated;

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: July 16, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR